SCHEMBL27199481

SCHEMBL27199481

Cn1cc(N)c2c(=O)n(C3CCOC3)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 6/20 0.37
MAP4K1 Q92918 1/20 0.35
P2RX7 Q99572 5/20 0.33
IL1B P01584 4/20 0.33
PIK3CA P42336 1/20 0.33
TYK2 P29597 3/20 0.33
LCK P06239 2/20 0.32
SRC P12931 1/20 0.32
TEK Q02763 1/20 0.32
FYN P06241 1/20 0.31
RET P07949 1/20 0.31
PDGFRB P09619 1/20 0.31
PDGFRA P16234 1/20 0.31
FLT1 P17948 1/20 0.31
LTK P29376 1/20 0.31
KDR P35968 1/20 0.31
MAP2K2 P36507 1/20 0.31
FLT3 P36888 1/20 0.31
CDK8 P49336 1/20 0.31
MAP2K1 Q02750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30498161 1.00 HTR3A (0.37) HTR3AMAP4K1P2RX7IL1BPIK3CA
SCHEMBL27199478 1.00 HTR3A (0.37) HTR3AMAP4K1P2RX7IL1BPIK3CA
Trifluoroacetic Acid SCHEMBL27199550 0.90 HTR3A (0.36) HTR3AMAP4K1P2RX7IL1BTYK2
SCHEMBL25752565 0.85 DHODH (0.34) HTR3A
Hydrochloric Acid SCHEMBL27199321 0.82 ALDH1A1 (0.36) HTR3A
SCHEMBL27199314 0.79 KDM4C (0.36) HTR3AP2RX7IL1BTYK2
SCHEMBL27199317 0.79 KDM4C (0.36) HTR3AP2RX7IL1BTYK2
Trifluoroacetic Acid SCHEMBL27199538 0.76 DPP4 (0.33)
SCHEMBL30895158 0.74 P2RX7 (0.35) HTR3AP2RX7IL1BTYK2
SCHEMBL30895094 0.74 P2RX7 (0.35) HTR3AP2RX7IL1BTYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 US disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR3A 3455/4885MAP4K1 160/4885P2RX7 3505/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 HTR3A 3455/4885MAP4K1 160/4885P2RX7 3505/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 HTR3A 3455/4885MAP4K1 160/4885P2RX7 3505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.